

**A multicentre phase III open-label randomized study in patients with advanced follicular lymphoma evaluating the benefit of maintenance therapy with rituximab after induction of response with chemotherapy plus rituximab in comparison with no maintenance therapy**

Dear Investigators,

First of all, we would like to thank all the investigators, research assistants and local representatives for their attendance to the Prima meeting in Amsterdam.

As the trial is doing very well so far, the GELA has been contacted by Roche, Genentech and Biogen-Idec who would like to **convert PRIMA trial into a registration study** in order to file an application for rituximab used as maintenance treatment for first line follicular NHL' in Europe and the USA.

The GELA and the companies agreed with this move, which will imply several changes.

**1) A new protocol amendment will be submitted** to the PRIMA Independent Data Safety Monitoring Committee which has been conveyed in the next weeks:

**3 major changes in the protocol will be proposed:**

- the use of 'progression free survival' instead of 'event free survival' as the primary endpoint, as requested by US and EU regulatory authorities.
- an increase in the sample size from currently 900 patients up to 1200 patients registered (then 900 randomized).

- The follow-up after the end of maintenance will be increased from 3 years to 5 years (a total of 7 years of observation after randomization).
- 2) We will then pursue our mutual efforts to **ensure the quality of the data** for this study and the timely flow of the information.
  - 3) **A CT-scan review will be organized.**
  - 4) All these efforts will be supported by a **substantial increase of the Investigator's fees.**


Contracts will be updated after the DSMB approval and as soon as each country will obtain approval.

We will do our best to move quickly and efficiently to this new step in the study, in order not to suspend registrations.

Again, congratulations for your participation in this study,

*Gilles Salles  
Delphine Germain & Stéphanie Baulu*

**Global World Recruitment - PRIMA Study**



**Status**

Induction treatment allocation :

- R-CHOP : 607 patients
- R-CVP : 190 patients
- R-FCM : 36 patients

Randomized : 306 patients

- Maintenance with Rituximab : 155 patients
- Observation : 151 patients

**ACTIVE COUNTRIES**

- Argentina
- Australia
- Belgium
- Brazil
- China
- Colombia
- Croatia
- Czech Republic
- Denmark
- Finland
- France
- India
- Israel
- Mexico
- Netherlands
- New-Zealand
- Peru
- Portugal
- Serbia
- Spain
- Thailand
- Turkey
- United Kingdom
- Uruguay
- Venezuela

Baseline documentation prior randomization

We do need to receive the baseline documentation of the CRF prior to be able to randomize a patient. **So don't forget to fill it in quickly**, to review it locally by your country monitor and to send it to the GELA-RC as soon as possible. This will avoid any delay at the time of randomization.

As data validation has started and a lot of patients are already randomized, Please send us the CRFs pages of Induction part and Randomization sheet (page 10 to 18 included).

For patient randomized in the observation arm (B), please don't forget the regular visits (every two months) and the assessments planned in the protocol.

**Don't forget that only patients with an available lymph node biopsy (obtained less than 4 months before) can be registered !**

For administrative information  
To download the protocol or other documents  
For a regular update of patients accrual per country,